These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28638122)

  • 1. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
    Stanley A; Ashrafi GH; Seddon AM; Modjtahedi H
    Sci Rep; 2017 Jun; 7(1):3964. PubMed ID: 28638122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
    Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
    Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
    Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
    Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
    Zhang X; Munster PN
    Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
    Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
    Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
    Thibault B; Jean-Claude B
    J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
    Browne BC; Eustace AJ; Kennedy S; O'Brien NA; Pedersen K; McDermott MS; Larkin A; Ballot J; Mahgoub T; Sclafani F; Madden S; Kennedy J; Duffy MJ; Crown J; O'Donovan N
    Breast Cancer Res Treat; 2012 Dec; 136(3):717-27. PubMed ID: 23117852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
    Browne BC; Crown J; Venkatesan N; Duffy MJ; Clynes M; Slamon D; O'Donovan N
    Ann Oncol; 2011 Jan; 22(1):68-73. PubMed ID: 20647220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
    Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Modjtahedi H
    BMC Cancer; 2013 Jan; 13():41. PubMed ID: 23367880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
    de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
    Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Src: a potential target for the treatment of triple-negative breast cancer.
    Tryfonopoulos D; Walsh S; Collins DM; Flanagan L; Quinn C; Corkery B; McDermott EW; Evoy D; Pierce A; O'Donovan N; Crown J; Duffy MJ
    Ann Oncol; 2011 Oct; 22(10):2234-40. PubMed ID: 21357651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
    Pichot CS; Hartig SM; Xia L; Arvanitis C; Monisvais D; Lee FY; Frost JA; Corey SJ
    Br J Cancer; 2009 Jul; 101(1):38-47. PubMed ID: 19513066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
    Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
    Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Solca F; Modjtahedi H
    Int J Oncol; 2016 Mar; 48(3):908-18. PubMed ID: 26781210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
    Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
    Nautiyal J; Majumder P; Patel BB; Lee FY; Majumdar AP
    Cancer Lett; 2009 Oct; 283(2):143-51. PubMed ID: 19398150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
    Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
    Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
    Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
    Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S; Montero JC; Ocaña A; Pandiella A
    J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.